Background/Aims: Cenesthopathy is mainly associated with schizophrenia; however, its neurobiological basis is nowadays unclear. The general objective was to explore clinical correlates of cenesthopathy and subjective cognitive complaints in schizophrenia. Methods: Participants (n = 30) meeting DSM-IV criteria for psychotic disorder were recruited from a psychiatry unit and assessed with: Association for Methodology and Documentation in Psychiatry (AMDP) system, Positive and Negative Syndrome Scale, Frankfurt Complaint Questionnaire (FCQ), and the Bonn Scale for the Assessment of Basic Symptoms (BSABS). For quantitative variables, means and Spearman correlation coefficients were calculated. Linear regression following backward method and principal component analysis with varimax rotation were used. Results: 83.3% of subjects (73.3% male, mean age, 31.5 years) presented any type of cenesthopathy; all types of cenesthetic basic symptoms were found. Cenesthetic basic symptoms significantly correlated with the AMDP category “fear and anancasm,” FCQ total score, and BSABS cognitive thought disturbances. In the regression analysis only 1 predictor, cognitive thought disturbances, entered the model. In the principal component analysis, a main component which accounted for 22.69% of the variance was found. Conclusions: Cenesthopathy, as assessed with the Bonn Scale (BSABS), is mainly associated with cog-nitive abnormalities including disturbances of thought initiative and mental intentionality, of receptive speech, and subjective retardation or pressure of thoughts.

1.
Graux J, Lemoine M, Gaillard P, Camus V: Les cénesthopathies: un trouble des émotions d’arrière-plan. Regards croisés des sciences cognitives et de la phénoménologie. Encéphale 2011; 37: 361–370.
2.
Jenkins G, Röhricht F: From cenesthesias to cenesthopathic schizophrenia: a historical and phenomenological review. Psychopathology 2007; 40: 361–368.
3.
Dupré E, Camus P: Les cénesthopathies. Encéphale 1907; 2: 616–631.
4.
Stanghellini G: Embodiment and schizophrenia. World Psychiatry 2009; 8: 56–59.
5.
Gross G, Huber G, Klosterkötter J, Linz M: Bonner Skala für die Beurteilung von Basis-symptomen (Bonn Scale for the Assessment of Basic Symptoms). Berlin, Springer, 1987.
6.
Gross G, Gerd H, Klosterkötter J, Linz M: BSABS – Bonn Scale for the Assessment of Basic Symptoms, English ed 1. Aachen, Shaker, 2008.
7.
Gross G, Huber G, Klosterkötter J, Linz M: Escala de Bonn para Evaluación de Síntomas Básicos (Moriñigo Escalante JC ed). Asunción, Universidad Nacional de Asunción, 1992.
8.
Huber G: Die coenästhetische Schizophrenie. Fortschr Neurol Psychiatr 1957; 25: 491–520.
9.
Simon AE, Borgwardt S, Lang UE, Roth B: Cenesthopathy in adolescence: an appraisal of diagnostic overlaps along the anxiety-hypochondriasis-psychosis spectrum. Compr Psychiatry 2014; 55: 1122–1129.
10.
Podoll K, Bollig G, Vogtmann T, Pothmann R, Robinson D: Cenesthetic pain sensations illustrated by an artist suffering from migraine with typical aura. Cephalalgia 1999; 19: 598–601.
11.
Erkwoh R: Psychopathology of vestibular aurae. Psychopathology 1990; 23: 129–135.
12.
Rommel O, Bokeloh M, Malin JP, Bräunig P, Strumpf M, Zenz M: Zönasthesie. Wich tige Differentialdiagnose bei chronischen Schmerzerkrankungen. Schmerz 1999; 13: 201–204.
13.
Ebel H, Gross G, Klosterkötter J, Huber G: Basic symptoms in schizophrenic and affective psychoses. Psychopathology 1989; 22: 224–232.
14.
Kornischka J, Schneider F: Delusion of pregnancy. A case report and review of the literature. Psychopathology 2003; 36: 276–278.
15.
Röhricht F, Gudi A, Lewis-Fernández R: Medically unexplained physical symptoms masking (cenesthopathic) schizophrenia: a case series. J Psychiatr Pract 2010; 16: 258–264.
16.
Röhricht F, Priebe S: Do cenesthesias and body image aberration characterize a subgroup in schizophrenia? Acta Psychiatr Scand 2002; 105: 276–282.
17.
Stanghellini G, Ballerini M, Fusar Poli P, Cutting J: Abnormal bodily experiences may be a marker of early schizophrenia? Curr Pharm Des 2012; 18: 392–398.
18.
Broome M, Harland R, Owen G, Stringaris A: Schizophrenia; in Broome M, Harland R, Owen G, Stringaris A (eds): The Maudsley Reader in Phenomenological Psychiatry. Cambridge, Cambridge University Press, 2012, chapt 16, pp 176–193.
19.
Sass LA, Parnas J: Schizophrenia, consciousness, and the self. Schizophr Bull 2003; 29: 427–444.
20.
Gallagher S: Neurocognitive models of schizophrenia: a neurophenomenological critique. Psychopathology 2004; 37: 8–19.
21.
Harney M: Naturalizing phenomenology – a philosophical imperative. Prog Biophys Mol Biol 2015; 119: 661–669.
22.
Kiefer M, Pulvermüller F: Conceptual representations in mind and brain: theoretical developments, current evidence and future directions. Cortex 2012; 48: 805–825.
23.
Bär K-J, Gaser C, Nenadic I, Sauer H: Transient activation of a somatosensory area in painful hallucinations shown by fMRI. Neuroreport 2002; 13: 805–808.
24.
Damasio AR: The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 1996; 351: 1413–1420.
25.
Bechara A, Damasio AR: The somatic marker hypothesis: a neural theory of economic decision. Games Econ Behav 2005; 52: 336–372.
26.
Rubino IA, Ciani N: A multivariate exploration of basic symptoms. Psychopathology 2002; 35: 267–271.
27.
Bobon D, Woggon B: The AMDP-system in clinical psychopharmacology. Br J Psychiatry 1986; 148: 467–468.
28.
Cuesta MJ, Peralta V: Integrating psychopathological dimensions in functional psychoses: a hierarchical approach. Schizophr Res 2001; 52: 215–229.
29.
López-Ibor JJ (ed): Asociación para la Me todología y Documentación en Psiquiatría. El sistema AMDP. Manual para la documentación de los hallazgos psiquiátricos. Madrid, Garsi, 1980.
30.
Kay S, Fiszbein A, Opler L: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.
31.
Nicotra E, Casu G, Piras S, Marchese G: On the use of the Positive and Negative Syndrome Scale in randomized clinical trials. Schizophr Res 2015; 165: 181–187.
32.
Peralta V, Cuesta MJ: Validación de la Escala de los Síndromes Positivo y Negativo (PANSS) en una muestra de esquizofrénicos españoles. Acta Luso-Españolas Neurol Psiquiatr Ciencias Afines 1994; 22: 171–177.
33.
Süllwold L: Die Selbstwahrnehmung defi-zitärer Störungen: psychologische Aspekte des Basisstörungskonzeptes; in Süllwold L, Huber G (eds): Schizophrene Basisstörungen. Berlin, Springer, 1986, pp 1–38.
34.
Jimeno N, Jimeno Valdés A, Vargas ML: El síndrome psicótico y el Inventario de Frankfurt. Conceptos y resultados. Barcelona, Springer Ibérica, 1996, p 184.
35.
Jimeno N, Jimeno Valdés A, Vargas ML, Dorado ML, Rodríguez MJ: Versión española de la escala BSABS. Presentación inicial. Sociedad Española de Psiquiatría (SEP) y Sociedad Española Psiquiatría Biológica (SEPB), La Psiquiatría en la década del cerebro, Congreso Sevilla95. Madrid, ELA, 1995, pp 483–487.
36.
Rajender G, Kanwal K, Rathore DM, Chaudhary D: Study of cenesthesias and body image aberration in schizophrenia. Indian J Psychiatry 2009; 51: 195–198.
37.
Raballo A, Maggini C: Experiential anomalies and self-centrality in schizophrenia. Psychopathology 2005; 38: 124–132.
38.
Hambrecht M, Lammertink M, Klosterkötter J, Matuschek E, Pukrop R: Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry 2002; 181(suppl 43):30–37.
39.
Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J: The Schizophrenia Proneness Instrument, adult version (SPI-A). Rome, Giovanni Fiority, 2007.
40.
Parnas J, Møller P, Kircher T, Thalbitzer J, Jansson L, Handest P, et al: EASE: Examination of Anomalous Self-Experience. Psychopathology 2005; 38: 236–258.
41.
Ciani N, Pezzarossa B, Curini A, Rubino IA: Self-report of basic symptoms among psychotic and nonpsychotic subjects. Psychol Rep 1999; 85: 621–632.
42.
Vargas ML, Jimeno N: Esquizofrenia e insuficiencia atencional. Escala ESEA para la evaluación subjetiva de errores atencionales. Va-lladolid, Secretariado de Publicaciones e Intercambio Editorial de la Universidad de Valladolid, 2002.
43.
Graham KT, Martin-Iverson MT, Holmes NP, Jablensky A, Waters F: Deficits in agency in schizophrenia, and additional deficits in body image, body schema, and internal timing, in passivity symptoms. Front Psychiatry 2014; 5: 1–11.
44.
Nelson B, Parnas J, Sass LA: Disturbance of minimal self (ipseity) in schizophrenia: clarification and current status. Schizophr Bull 2014; 40: 479–482.
45.
Lanteri-Laura G: Psychasthenia: history and evolution of the P. Janet concept. Encéphale 1994; 20(Spec Nov):551–557.
46.
Peralta V, Cuesta MJ: Eugen Bleuler and the schizophrenias: 100 years after. Schizophr Bull 2011; 37: 1118–1120.
47.
Poyurovsky M, Zohar J, Glick I, Koran LM, Weizman R, Tandon R, et al: Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry 2012; 53: 480–483.
48.
Tonna M, Ottoni R, Paglia F, Ossola P, De Panfilis C, Marchesi C: Obsessive-compulsive symptom severity in schizophrenia: a Janus Bifrons effect on functioning. Eur Arch Psychiatry Clin Neurosci 2016; 266: 63–69.
49.
Tonna M, Ottoni R, Paglia F, Ossola P, De Panfilis C, Marchesi C: Obsessive-compulsive symptoms interact with disorganization in influencing social functioning in schizophrenia. Schizophr Res 2016; 171: 35–41.
50.
Bedia MG, Di Paolo E: Unreliable gut feelings can lead to correct decisions: the somatic marker hypothesis in non-linear decision chains. Front Psychol 2012; 3: 384.
51.
Maggini C, Raballo A, Salvatore P: Depersonalization and basic symptoms in schizophrenia. Psychopathology 2002; 35: 17–24.
52.
Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J, et al: Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early – and additional memory dysfunction in the late – prodromal state. Schizophr Bull 2011; 37: 861–873.
53.
Schultze-Lutter F, Debbané M, Theodoridou A, Wood SJ, Raballo A, Michel C, et al: Revisiting the basic symptom concept: toward translating risk symptoms for psychosis into neurobiological targets. Front Psychiatry 2016; 7: 9.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.